|Bid||3.45 x 900|
|Ask||4.90 x 800|
|Day's Range||3.6800 - 3.8600|
|52 Week Range||1.2000 - 4.8660|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. In the final minutes of trading on Thursday, the company's shares hit $4.20. A year ago, they were trading ...
Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient.
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.
Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 -- Chiasma,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...
Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has completed enrollment of its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers). This trial is being conducted under a Special Protocol Assessment (“SPA”) agreement with the U.S. Food and Drug Administration (“FDA”) to support potential regulatory approval in the United States of its investigational octreotide capsules, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. Chiasma exceeded target enrollment of 50 patients in the trial with a total of 56 acromegaly patients randomized in 17 countries worldwide, including 21 patients from the U.S.
If you’re interested in Chiasma Inc (NASDAQ:CHMA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impactRead More...
The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.25. A year ago, they were trading at $1.45. _____ ...
The Waltham, Massachusetts-based company said it had a loss of 29 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.45. A year ago, they were trading at $1.60. _____ ...
The Waltham, Massachusetts-based company said it had a loss of 25 cents per share. Losses, adjusted for restructuring costs, came to 21 cents per share. In the final minutes of trading on Tuesday, the ...
Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...
Examining Chiasma Inc’s (NASDAQ:CHMA) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...